Arcutis Biotherapeutics Inc. (ARQT) saw its shares surge 9.02% in the last 24 hours during Tuesday's intraday trading session, following the release of the company's impressive fourth quarter 2024 financial results.

The biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. According to the earnings report, net product revenue for ZORYVE surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indications of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.

ZORYVE has rapidly gained market share and is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States. The company's total revenue for Q4 came in at $71.4 million, beating analysts' estimates of $60.16 million, while its reported loss of $0.09 per share also surpassed expectations of a $0.24 loss.